IRON - Disc Medicine, Inc. Annual Revenue Growth (Last Twelve Months)

Public company logo of Disc Medicine, Inc. (IRON)

Disc Medicine, Inc. (IRON) focuses on the development of bitopertin for the treatment of porphyria, awaiting FDA approval and potential M&A deals. A team of hematology experts strives for scientific breakthroughs, driven by stock option incentives. The rolling annual revenue growth from sales visualizes income dynamics, where 0.00 reflects the metric's baseline. However, high research and development costs are depleting the company's capital.

Sales Growth YoY (TTM): Disc Medicine Corp (IRON) for 02/11/2024 - 11/18/2026

Summary analytical data breakdowns for Disc Medicine Inc (IRON)

Summary company analytics:Disc Medicine, Inc.
Brand item of Disc Medicine

Disc Medicine, Inc. maintains its status as a leader in the development of innovative therapies for hematological blood diseases. By analyzing the year-over-year sales trend over a 12-month period, an investor can observe the rolling year revenue dynamics. The current value of 0.00 reflects the percentage growth in revenue relative to the same window from the previous year. This indicator confirms the operational efficiency and the stability of the market positions of this highly reputable biotechnology brand.